These findings position NPC integrity as a promising therapeutic target in AD, with potential interventions including Nup-stabilizing agents to restore nuclear-cytoplasmic balance and small-molecule inhibitors designed to disrupt pathogenic Tau-Nup interactions, thereby slowing disease progression. The gene discussed is NPC1; the disease is Alzheimer disease.